ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v13i4.1616ppharm-1450Research ArticleДИАГНОСТИКА В ПЕДИАТРИИPEDIATRIC DIAGNOSTICSАллергенспецифическая иммунотерапия у детей: современное состояние вопросаAllergen-Specific Child Immunotherapy: Current State of Affairshttps://orcid.org/0000-0001-7398-0562ВишнёваЕ. А.VishnevaE. A.

кандидат медицинских наук, заместитель директора НИИ педиатрии по научной работе, заведующая отделом стандартизации и клинической фармакологии НЦЗД, врач аллерголог-иммунолог отделения восстановительного лечения детей с аллергическими болезнями и заболеваниями органов дыхания НИИ педиатрии НЦЗД,

119991, Москва, Ломоносовский проспект, д. 2, стр. 1

vishneva@nczd.ruhttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaL. S.https://orcid.org/0000-0001-5665-7835АлексееваА. А.AlekseevaA. A.https://orcid.org/0000-0002-3678-7939СелимзяноваЮ. Г.SelimzyanovaL. R.ЛевинаЮ. Г.LevinaJ. G.ЭфендиеваК. Е.EfendievaK. E.https://orcid.org/0000-0002-3696-3293ДобрынинаЕ. А.DobryninaE. A.Научный центр здоровья детейРоссияScientific Center of Children’s HealthRussian FederationНаучный центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияScientific Center of Children’s Health; Sechenov First Moscow State Medical University; Pirogov Russian National Research Medical UniversityRussian FederationНаучный центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Center of Children’s Health; Sechenov First Moscow State Medical UniversityRussian FederationНаучный центр здоровья детей; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияScientific Center of Children’s Health; Pirogov Russian National Research Medical UniversityRussian Federation201615112016134404408Copyright © Вишнёва Е.А., Намазова-Баранова Л.С., Алексеева А.А., Селимзянова Ю.Г., Левина Ю.Г., Эфендиева К.Е., Добрынина Е.А., 20162016Вишнёва Е.А., Намазова-Баранова Л.С., Алексеева А.А., Селимзянова Ю.Г., Левина Ю.Г., Эфендиева К.Е., Добрынина Е.А.Vishneva E.A., Namazova-Baranova L.S., Alekseeva A.A., Selimzyanova L.R., Levina J.G., Efendieva K.E., Dobrynina E.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1450

Статья посвящена аллергенспецифической иммунотерапии (АСИТ) — единственному этиопатогенетическому методу терапии аллергической патологии. Способствуя формированию иммунологической толерантности, АСИТ модифицирует течение болезни, предотвращает возникновение новой или утяжеление имеющейся сенсибилизации, тем самым предупреждая развитие астмы, что особенно актуально для пациентов детского возраста. Авторами представлены основные особенности механизма действия и условия достижения запланированного эффекта. Рассматриваются ключевые противопоказания к назначению АСИТ, принципы выбора соответствующего аллергена для лечения и особенности его введения детям как с моносенсибилизацией, так и чувствительным к группе аллергенов. Обозначены дальнейшие перспективы развития исследований и уже имеющиеся достижения данной медицинской технологии.

The article is devoted to allergen-specific immunotherapy (ASIT) — the only etiopathogenic therapy method for allergic diseases. By promoting the formation of immunological tolerance, ASIT modifies the course of the disease, prevents the occurrence of new or the worsening of existing sensitizations, thereby preventing the development of asthma, which is especially important for pediatric patients. The authors present the mechanism of action and its main features and conditions with regard to achieving the planned effect. Considered are the key contraindications to ASIT, the principles of selecting the appropriate allergen for the treatment and features of its introduction to both children with mono sensitization and children sensitive to the allergen group. Further prospects of research development and existing achievements of this medical technology are mentioned.

аллергенспецифическая иммунотерапиясублингвальная аллергенспецифическая иммунотерапияпатогенетическая терапия аллергиииндукция иммунной толерантностидетиallergen immunotherapy sublingual allergen immunotherapyallergy pathogenetic therapyimmune tolerance induction and childrenReferencesJutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3): 556–568. doi: 10.1016/j.jaci.2015.04.047.Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3): 556–568. doi: 10.1016/j.jaci.2015.04.047.Pitsios C, Demoly P, Bilo MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015;70(8):897–909. doi: 10.1111/all.12638.Pitsios C, Demoly P, Bilo MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015;70(8):897–909. doi: 10.1111/all.12638.Jutel M, Akdis CA. Immunological mechanisms of allergenspecific immunotherapy. Allergy. 2011;66(6):725–732. doi: 10.1111/j.1398-9995.2011.02589.x.Jutel M, Akdis CA. Immunological mechanisms of allergenspecific immunotherapy. Allergy. 2011;66(6):725–732. doi: 10.1111/j.1398-9995.2011.02589.x.Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621–631. doi: 10.1016/j.jaci.2013.12.1088.Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621–631. doi: 10.1016/j.jaci.2013.12.1088.Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO — ARIA — GA(2)LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013;6(1):17. doi: 10.1186/1939-4551-6-17.Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO — ARIA — GA(2)LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013;6(1):17. doi: 10.1186/1939-4551-6-17.Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy. 2010; 40(10):1442–1460. doi: 10.1111/j.1365-2222.2010.03585.x.Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy. 2010; 40(10):1442–1460. doi: 10.1111/j.1365-2222.2010.03585.x.Borres MP, Ebisawa M, Eigenmann PA. Use of allergen components begins a new era in pediatric allergology. Pediatr Allergy Immunol. 2011;22(5):454–461. doi: 10.1111/j.1399-3038.2011.01197.x.Borres MP, Ebisawa M, Eigenmann PA. Use of allergen components begins a new era in pediatric allergology. Pediatr Allergy Immunol. 2011;22(5):454–461. doi: 10.1111/j.1399-3038.2011.01197.x.Shreffler WG. Microarrayed recombinant allergens for diagnostic testing. J Allergy Clin Immunol. 2011;127(4):843–849; quiz 850–841. doi: 10.1016/j.jaci.2011.02.011.Shreffler WG. Microarrayed recombinant allergens for diagnostic testing. J Allergy Clin Immunol. 2011;127(4):843–849; quiz 850–841. doi: 10.1016/j.jaci.2011.02.011.Weber RW. Cross-reactivity of pollen allergens: impact on allergen immunotherapy. Ann Allergy Asthma Immunol. 2007;99(3): 203–212. doi: 10.1016/S1081-1206(10)60654-0.Weber RW. Cross-reactivity of pollen allergens: impact on allergen immunotherapy. Ann Allergy Asthma Immunol. 2007;99(3): 203–212. doi: 10.1016/S1081-1206(10)60654-0.Santos A, Van Ree R. Profilins: mimickers of allergy or relevant allergens? Int Arch Allergy Immunol. 2011;155(3):191-204. doi: 10.1159/000321178.Santos A, Van Ree R. Profilins: mimickers of allergy or relevant allergens? Int Arch Allergy Immunol. 2011;155(3):191-204. doi: 10.1159/000321178.Sastre J, Landivar ME, Ruiz-Garcia M, et al. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy. 2012;67(5):709–711. doi: 10.1111/j.1398-9995.2012.02808.x.Sastre J, Landivar ME, Ruiz-Garcia M, et al. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy. 2012;67(5):709–711. doi: 10.1111/j.1398-9995.2012.02808.x.Calderon MA, Cox L, Casale TB, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol. 2012;129(4):929–934. doi: 10.1016/j.jaci.2011.11.019.Calderon MA, Cox L, Casale TB, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol. 2012;129(4):929–934. doi: 10.1016/j.jaci.2011.11.019.Passalacqua G, Nowak-Wegrzyn A, Canonica GW. Local side effects of sublingual and oral immunotherapy. J Allergy Clin Immunol Pract. Forthcoming 2016. doi: 10.1016/j.jaip.2016.06.020.Passalacqua G, Nowak-Wegrzyn A, Canonica GW. Local side effects of sublingual and oral immunotherapy. J Allergy Clin Immunol Pract. Forthcoming 2016. doi: 10.1016/j.jaip.2016.06.020.Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013;132(1):93–98. doi: 10.1016/j.jaci.2013.03.039.Passalacqua G, Baena-Cagnani CE, Bousquet J, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013;132(1):93–98. doi: 10.1016/j.jaci.2013.03.039.Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125(3):569–574.e7. doi: 10.1016/j.jaci.2009.10.060.Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125(3):569–574.e7. doi: 10.1016/j.jaci.2009.10.060.Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann Allergy Asthma Immunol. 2008;101(1):96–100. doi: 10.1016/S1081-1206(10)60841-1.Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann Allergy Asthma Immunol. 2008;101(1):96–100. doi: 10.1016/S1081-1206(10)60841-1.Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol. 2004;92(2):225–227. doi: 10.1016/S1081-1206(10)61551-7.Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol. 2004;92(2):225–227. doi: 10.1016/S1081-1206(10)61551-7.Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol. 2000;106(5):840–843. doi: 10.1067/mai.2000.110468.Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol. 2000;106(5):840–843. doi: 10.1067/mai.2000.110468.Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2007;99(1): 82–86. doi: 10.1016/S1081-1206(10)60626-6.Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2007;99(1): 82–86. doi: 10.1016/S1081-1206(10)60626-6.Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854–867. doi: 10.1111/all.12383.Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69(7):854–867. doi: 10.1111/all.12383.Вишнева Е.А., Намазова-Баранова Л.С., Алексеева А.А. и др. Аллергенспецифическая иммунотерапия у детей. Стандартизация подходов к оценке эффективности // Педиатрическая фармакология. — 2015. — Т. 12. — № 2. — С. 173–179. [Vishneva EA, Namazova-Baranova LS, Alekseeva AA, et al. Allergenspecific immunotherapy in children. Standardizing the efficacy evaluation approaches. Pediatric pharmacology. 2015;12(2):173–179. (In Russ).] doi: 10.15690/pf.v12i2.1280.Вишнева Е.А., Намазова-Баранова Л.С., Алексеева А.А. и др. Аллергенспецифическая иммунотерапия у детей. Стандартизация подходов к оценке эффективности // Педиатрическая фармакология. — 2015. — Т. 12. — № 2. — С. 173–179. [Vishneva EA, Namazova-Baranova LS, Alekseeva AA, et al. Allergenspecific immunotherapy in children. Standardizing the efficacy evaluation approaches. Pediatric pharmacology. 2015;12(2):173–179. (In Russ).] doi: 10.15690/pf.v12i2.1280.Bousquet PJ, Combescure C, Klossek JM, et al. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol. 2009;123(6):1349–1354. doi: 10.1016/j.jaci.2009.02.033.Bousquet PJ, Combescure C, Klossek JM, et al. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol. 2009;123(6):1349–1354. doi: 10.1016/j.jaci.2009.02.033.Abramson MJ, Puy RM, Weiner JM. Injection allergen immuno therapy for asthma. Cochrane Database Syst Rev. 2010; (8):CD001186. doi: 10.1002/14651858.CD001186.pub2.Abramson MJ, Puy RM, Weiner JM. Injection allergen immuno therapy for asthma. Cochrane Database Syst Rev. 2010; (8):CD001186. doi: 10.1002/14651858.CD001186.pub2.Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2014;124(3):616–627. doi: 10.1002/lary.24295.Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2014;124(3):616–627. doi: 10.1002/lary.24295.Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134(3):568–575.e7. doi: 10.1016/j.jaci.2014.03.019.Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134(3):568–575.e7. doi: 10.1016/j.jaci.2014.03.019.Marogna M, Braidi C, Bruno ME, et al. The contribution of sublingual immunotherapy to the achievement of control in birchrelated mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr). 2013;41(4):216–224. doi: 10.1016/j.aller.2012.07.004.Marogna M, Braidi C, Bruno ME, et al. The contribution of sublingual immunotherapy to the achievement of control in birchrelated mild persistent asthma: a real-life randomised trial. Allergol Immunopathol (Madr). 2013;41(4):216–224. doi: 10.1016/j.aller.2012.07.004.Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609. doi: 10.1378/chest.06-1425.Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609. doi: 10.1378/chest.06-1425.Tam HH, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. Allergy. 2016;71(9):1345–1356. doi: 10.1111/all.12932.Tam HH, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review. Allergy. 2016;71(9):1345–1356. doi: 10.1111/all.12932.Вишнева Е.А., Намазова-Баранова Л.С. Аллерген специ фическая иммунотерапия у детей: перспективы профилактики и лечения // Педиатрическая фармакология. — 2015. — Т. 12. — № 5. — С. 532–536. [Vishnyova EA, Namazova-Baranova LS. Allergen-specific immunotherapy in children: prospects of prevention and treatment. Pediatric pharmacology. 2015;12(5):532–536. (In Russ).] doi: 10.15690/pf.v12i5.1454.Вишнева Е.А., Намазова-Баранова Л.С. Аллерген специ фическая иммунотерапия у детей: перспективы профилактики и лечения // Педиатрическая фармакология. — 2015. — Т. 12. — № 5. — С. 532–536. [Vishnyova EA, Namazova-Baranova LS. Allergen-specific immunotherapy in children: prospects of prevention and treatment. Pediatric pharmacology. 2015;12(5):532–536. (In Russ).] doi: 10.15690/pf.v12i5.1454.Dhami S, Nurmatov U, Halken S, et al. Allergen immunotherapy for the prevention of allergic disease: protocol for a systematic review. Pediatr Allergy Immunol. 2016;27(3):236–241. doi: 10.1111/pai.12524.Dhami S, Nurmatov U, Halken S, et al. Allergen immunotherapy for the prevention of allergic disease: protocol for a systematic review. Pediatr Allergy Immunol. 2016;27(3):236–241. doi: 10.1111/pai.12524.

The authors declare that there are no conflicts of interest present.